Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

NCT03927105 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

4

Enrollment

OTHER

Sponsor class

Conditions

Peripheral T Cell Lymphoma

Interventions

DRUG: Nivolumab
DRUG: cabiralizumab

Sponsor

University of Michigan Rogel Cancer Center

Collaborators

[object Object]